ClinicalTrials.gg
Not yet recruitingNCT07039760Updated Sep 11, 2026

Asciminib With or Without Sildenafil for Brain Tumors

An Early Phase 1 interventional study of Asciminib and Sildenafil in Brain Tumor, sponsored by Washington University School of Medicine. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 39 Years. Per ClinicalTrials.gov, last updated 2026-09-11.

Sponsored by Washington University School of Medicine · Early Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years to 39 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Brain Neoplasms by Washington University School of Medicine — 5 open to participants now, 5 under way, none of them phase 3. Brain Neoplasms · Washington University School of Medicine.

Planned enrollment
8th of 12
12 · median 20
Started
2026
with 1 other
Phase 1
6 of 14
3 open now
Registered
13th of 14
by date

Among the 14 studies in Brain Neoplasms by Washington University School of Medicine, this one is the 8th largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2026, is one of 6 in phase 1, and was the 13th registered.

Brain Neoplasms

2,441 studies on the registry are indexed under Brain Neoplasms; 541 are open to participants now.

Browse Brain Neoplasms studies →

Open to participants now

5 of the 14 studies in Brain Neoplasms by Washington University School of Medicine are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 425 Brain Neoplasms studies recruiting now, 286 (67%) set no upper age limit and 82 (19%) stop at 75 or younger; 80 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 39 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Brain Neoplasms by Washington University School of Medicine, or all of them as a file.
02

Study summary

Dissemination of medulloblastoma is an independent risk factor of poor prognosis. Dissemination of medulloblastoma at recurrence is nearly universally fatal. ABL1 and 2 have been recently found to mediate the dissemination of medulloblastoma. Genetically inactivating ABL1 and 2 resulted in decreased leptomeningeal medulloblastoma and improved overall survival (OS) in rodent models. ABL kinases have also been shown to play a role in the malignant properties of glioblastoma. Asciminib is an FDA approved for the treatment of chronic myeloid leukemia and is well tolerated, likely due to its specificity for ABL1 and ABL2. Asciminib is a P-glycoprotein (P-gp) substrate and thus may be susceptible to being pumped out of tumor cells and brain endothelial cells. It is unclear if asciminib can enter the central nervous system (CNS) and brain tumors in adequate concentration to have anti-tumor effects.

03

Conditions studied

  • Brain Tumor

Browse trials for

Keywords

  • Asciminib
  • Sildenafil
  • ABL1
  • ABL2
  • Tyrosine kinase inhibitor
  • Pediatric brain tumor
  • Brain tumor
  • Pharmacokinetics
  • Pharmacodynamics
04

Who can participate

Ages eligible
18 Years to 39 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ages 18-39 years old, inclusive.
  • Radiographic evidence of a recurrent/progressive brain tumor.
  • Tumor must be predominantly in an intraparenchymal location.
  • Deemed operable (able to be resected or have an open or stereotactic needle ) by treating neurosurgeon.
  • Performance Status of ≥ 2. Patients who are unable to walk because of paralysis but who are up in a wheelchair will be considered ambulatory for the purposes of the performance score.
  • Bone Marrow:

    • (Absolute neutrophil count) ≥ 1000/µl (unsupported).
    • ≥ 100,000/µl (may be supported by transfusion).
    • > 8 g/dL (may be supported by transfusion).
  • Renal:

    • Serum creatinine ≤ upper limit of institutional normal.
  • Hepatic:

    • ≤ 1.5 times for age.
    • (SGPT) ≤ 3 times institutional upper limit of normal for age.
    • AST (SGOT) ≤ 3 times institutional upper limit of normal for age.
  • Ability to understand and willingness to sign an IRB approved written document. Legally authorized representatives may sign and give informed consent on behalf of study participants. All patients and/or their parents or legal guardians must sign an IRB approved written informed consent document.

Exclusion criteria

Exclusion Criteria:

  • Tumors suspected to be pituitary tumors or tumors of the meninges.
  • Tumors that are suspected of a non-CNS primary location or history of non-CNS ).
  • Unable to take tablets orally
  • Pregnant and/or breastfeeding. Subjects of must have a negative serum or urine pregnancy test within 10 days prior to Day 1.
  • Active infection requiring treatment or an unexplained febrile (> 101.5o F) illness.
  • Known disease or infection.
  • Any active renal, cardiac (congestive cardiac failure, myocardial infarction, myocarditis), or pulmonary disease.
  • Any unrelated systemic illness (serious infections or significant cardiac, pulmonary, hepatic or other organ dysfunction).
  • Inability to return for follow-up visits or obtain follow-up studies required to assess toxicity to therapy.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    Group A: Asciminib

    Patients will receive two doses of 40 mg oral asciminib taken 12 hours apart. Surgery or biopsy should occur approximately 3 hours after last dose of asciminib.

    Drug: Asciminib · Procedure: Surgical resection or biopsy

  • Experimental
    Group B: Asciminib + Sildenafil

    Patients will receive two doses of 40 mg oral asciminib taken 12 hours apart plus two doses of 20 mg oral sildenafil taken 12 hours apart. Surgery or biopsy should occur approximately 3 hours after last dose of asciminib and sildenafil.

    Drug: Asciminib · Drug: Sildenafil · Procedure: Surgical resection or biopsy

Interventions

  • Commercially available stock

  • Commercially available stock

  • ProcedureSurgical resection or biopsy

    Standard of care

06

What researchers measure

Primary outcomes

  1. Tumor:plasma ratio of asciminib

    Time frame: At time of surgical resection or biopsy (day 1)

  2. Tumor:plasma ratio of asciminib with sildenafil

    Time frame: At time of surgical resection or biopsy (day 1)

Secondary outcomes

  1. Change in plasma levels of asciminib

    Time frame: Baseline, time of tumor resection/biopsy (day 1), and 8 (+/- 4 hours) after surgical resection or biopsy

  2. Expression of c-MYC in brain tumor specimens

    Time frame: At time of surgical resection or biopsy (day 1)

  3. Expression of p-CRKL in brain tumor specimens

    Time frame: At time of surgical resection or biopsy (day 1)

  4. Proportion of patients with unacceptable toxicity

    Time frame: From start of treatment (day 1) through 3 weeks following asciminib

07

Study locations

1 site
  • Washington University School of Medicine/St. Louis Children's Hospital
    St Louis, Missouri 63110, United States
    • Eric Thompson, M.D. · Contactpedshemonctrialreferral@wustl.edu · 314-454-4707
    • Eric Thompson, M.D. · Principal investigator
    • Mohamed Abdelbaki, M.D. · Sub investigator
    • Nicole Brossier, M.D., Ph.D. · Sub investigator
    • Andrew Cluster, M.D. · Sub investigator
    • Michael Huang, M.D. · Sub investigator
    • Sean McEvoy, M.D. · Sub investigator
    • Jarod Roland, M.D. · Sub investigator
    • Jennifer Strahle, M.D. · Sub investigator
    • Jing Wang, Ph.D. · Sub investigator
    • Tanner Johanns, M.D., Ph.D. · Sub investigator
    • Omar Butt, M.D. · Sub investigator
    • Milan Chheda, M.D. · Sub investigator
    • Albert Kim, M.D., Ph.D. · Sub investigator
    • Eric Leuthardt, M.D. · Sub investigator
    • Dimitrios Mathios, M.D. · Sub investigator
    • Bhuvic Patel, M.D. · Sub investigator
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Apr 2028, 17 months later.

Of 176 non-industry phase 1 interventional studies under Brain Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 84. This study's planned 17 months is below that.

Counting every sponsor, half of 205 studies reached it within 54 months; a quarter within 36 and three quarters within 84.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2025
First posted
Jun 26, 2025
StartEst.
Oct 31, 2026
Primary completionEst.
Apr 30, 2028
CompletionEst.
May 31, 2028
Last update
Sep 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07039760
Responsible party
Sponsor
First posted
Jun 26, 2025
Start date
Oct 31, 2026 (estimated)
Primary completion
Apr 30, 2028 (estimated)
Completion
May 31, 2028 (estimated)
Last update
Sep 11, 2026

Study contacts

Eric Thompson, M.D.
Contact
pedshemonctrialreferral@wustl.edu
314-454-4707
Eric Thompson, M.D.
principal investigator · Washington University School of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Asciminib

Start the discussion